{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:55:40Z","timestamp":1783338940479,"version":"3.54.6"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To assess the early physiologic response to angiotensin-II treatment in patients with coronavirus disease 2019\u2013induced respiratory failure and distributive shock.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Retrospective consecutive-sample cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Three medical ICUs in New York during the coronavirus disease 2019 outbreak.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>All patients were admitted to the ICU with respiratory failure and were receiving norepinephrine for distributive shock.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The treatment groups were patients who received greater than or equal to 1 hour of angiotensin-II treatment. Time-zero was the time of angiotensin-II initiation. Controls were identified using a 2:1 hierarchical process that matched for 1) date and unit of admission; 2) specific organ support modalities; 3) age; 4) chronic lung, cardiovascular, and kidney disease; and 5) sex. Time-zero in the control group was 21 hours post vasopressor initiation, the mean duration of vasopressor therapy prior to angiotensin-II initiation in the treated group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>Main outcomes were trajectories of vasopressor requirements (in norepinephrine-equivalent dose) and mean arterial pressure. Additionally assessed trajectories were respiratory (Pa<jats:sc>o<\/jats:sc>\n                                 <jats:sub>2<\/jats:sub>\/F<jats:sc>io<\/jats:sc>\n                                 <jats:sub>2<\/jats:sub>, Pa<jats:sc>co<\/jats:sc>\n                                 <jats:sub>2<\/jats:sub>), metabolic (pH, creatinine), and coagulation (<jats:sc>d<\/jats:sc>-dimer) dysfunction indices after time-zero. We also recorded adverse events and clinical outcomes. Trajectories were analyzed using mixed-effects models for immediate (first 6\u2009hr), early (48\u2009hr), and sustained (7 d) responses. Twenty-nine patients (<jats:italic toggle=\"yes\">n<\/jats:italic> = 10 treated, <jats:italic toggle=\"yes\">n<\/jats:italic> = 19 control) were identified. Despite matching, angiotensin-II\u2013treated patients had markedly greater vasopressor requirements (mean: 0.489 vs 0.097 \u00b5g\/kg\/min), oxygenation impairment, and acidosis at time-zero. Nonetheless, angiotensin-II treatment was associated with an immediate and sustained reduction in norepinephrine-equivalent dose (6\u2009hr model: \u03b2 = \u20130.036 \u00b5g\/kg\/min\/hr; 95% CI: \u20130.054 to \u20130.018 \u00b5g\/kg\/min\/hr, <jats:italic toggle=\"yes\">p<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub>=0.0002) (7 d model: \u03b2 = \u20130.04 \u00b5g\/kg\/min\/d, 95% CI: \u20130.05 to \u20130.03 \u00b5g\/kg\/min\/d; <jats:italic toggle=\"yes\">p<\/jats:italic>\n                                 <jats:sub>interaction<\/jats:sub> = 0.0002). Compared with controls, angiotensin-II\u2013treated patients had significantly faster improvement in mean arterial pressure, hypercapnia, acidosis, baseline-corrected creatinine, and <jats:sc>d<\/jats:sc>-dimer. Three thrombotic events occurred, all in control patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Angiotensin-II treatment for coronavirus disease 2019\u2013induced distributive shock was associated with rapid improvement in multiple physiologic indices. Angiotensin-II in coronavirus disease 2019\u2013induced shock warrants further study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000230","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T13:34:40Z","timestamp":1601386480000},"page":"e0230","source":"Crossref","is-referenced-by-count":15,"title":["Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019\u2013Induced Vasodilatory Shock: A Retrospective Matched Cohort Study"],"prefix":"10.1097","volume":"2","author":[{"given":"Daniel E.","family":"Leisman","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Sepsis Research Laboratory, Feinstein Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiore","family":"Mastroianni","sequence":"additional","affiliation":[{"name":"Sepsis Research Laboratory, Feinstein Institute for Medical Research, Manhasset, NY."},{"name":"Division of Pulmonary and Critical Care Medicine, Northwell Health, New Hyde Park, NY."},{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Fisler","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."},{"name":"Division of Critical Care Medicine, Department of Pediatrics, Cohen Children\u2019s Medical Center, New Hyde Park, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareen","family":"Shah","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."},{"name":"Division of Critical Care Medicine, Department of Pediatrics, Cohen Children\u2019s Medical Center, New Hyde Park, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Hasan","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Northwell Health, New Hyde Park, NY."},{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Narasimhan","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Northwell Health, New Hyde Park, NY."},{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Sepsis Research Laboratory, Feinstein Institute for Medical Research, Manhasset, NY."},{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."},{"name":"Division of Critical Care Medicine, Department of Pediatrics, Cohen Children\u2019s Medical Center, New Hyde Park, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford S.","family":"Deutschman","sequence":"additional","affiliation":[{"name":"Sepsis Research Laboratory, Feinstein Institute for Medical Research, Manhasset, NY."},{"name":"Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY."},{"name":"Division of Critical Care Medicine, Department of Pediatrics, Cohen Children\u2019s Medical Center, New Hyde Park, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"R1-20231023","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study.","volume":"395","author":"Cummings","year":"2020","journal-title":"Lancet"},{"key":"R2-20231023","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China.","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R3-20231023","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State.","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"R4-20231023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.kint.2020.05.006","article-title":"Acute kidney injury in patients hospitalized with COVID-19.","volume":"98","author":"Hirsch","year":"2020","journal-title":"Kidney Int"},{"key":"R5-20231023","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19.","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"R6-20231023","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","article-title":"Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19).","volume":"48","author":"Alhazzani","year":"2020","journal-title":"Crit Care Med"},{"key":"R7-20231023","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1164\/rccm.201604-0862CP","article-title":"Potentially inadvertent immunomodulation: Norepinephrine use in sepsis.","volume":"194","author":"Stolk","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-20231023","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock.","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20231023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40256-018-0297-9","article-title":"FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock.","volume":"19","author":"Senatore","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"R10-20231023","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.2006070707","article-title":"Human T and natural killer cells possess a functional renin-angiotensin system: Further mechanisms of angiotensin II-induced inflammation.","volume":"18","author":"Jurewicz","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R11-20231023","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1681\/ASN.2016101066","article-title":"Immunologic effects of the renin-angiotensin system.","volume":"28","author":"Crowley","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R12-20231023","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","article-title":"Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II.","volume":"46","author":"Tumlin","year":"2018","journal-title":"Crit Care Med"},{"key":"R13-20231023","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock.","author":"Bellomo","year":"2020 Jul 1. [online ahead of print]","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-20231023","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00134-020-06059-6","article-title":"Facing COVID-19 in the ICU: Vascular dysfunction, thrombosis, and dysregulated inflammation.","volume":"46","author":"Leisman","year":"2020","journal-title":"Intensive Care Med"},{"key":"R15-20231023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure.","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"R16-20231023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jamcollsurg.2007.07.026","article-title":"Angiotensin II type 2 receptor provides an endogenous brake during inflammation-induced microvascular fluid leak.","volume":"205","author":"Ereso","year":"2007","journal-title":"J Am Coll Surg"},{"key":"R17-20231023","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","article-title":"Coagulopathy of Coronavirus disease 2019.","volume":"48","author":"Iba","year":"2020","journal-title":"Crit Care Med"},{"key":"R18-20231023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/CCM.0000000000003567","article-title":"Ten pearls and pitfalls of propensity scores in critical care research: A guide for clinicians and researchers.","volume":"47","author":"Leisman","year":"2019","journal-title":"Crit Care Med"},{"key":"R19-20231023","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13054-018-2202-y","article-title":"Angiotensin converting enzyme defects in shock: Implications for future therapy.","volume":"22","author":"Chawla","year":"2018","journal-title":"Crit Care"},{"key":"R20-20231023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000349963","article-title":"Diagnosis of acute kidney injury using functional and injury biomarkers: Workgroup statements from the tenth acute dialysis quality initiative consensus conference.","volume":"182","author":"McCullough","year":"2013","journal-title":"Contrib Nephrol"},{"key":"R21-20231023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13054-020-02928-0","article-title":"Angiotensin II infusion in COVID-19-associated vasodilatory shock: A case series.","volume":"24","author":"Zangrillo","year":"2020","journal-title":"Crit Care"},{"key":"R22-20231023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"R23-20231023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCM.0000000000003531","article-title":"Causal inference from observational data: New guidance from pulmonary, critical care, and sleep journals.","volume":"47","author":"Maslove","year":"2019","journal-title":"Crit Care Med"},{"key":"R24-20231023","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.annemergmed.2014.03.025","article-title":"Looking through the retrospectoscope: Reducing bias in emergency medicine chart review studies.","volume":"64","author":"Kaji","year":"2014","journal-title":"Ann Emerg Med"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T17:06:42Z","timestamp":1698080802000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000230","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}